BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) in patients with BCG-naive, high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results